<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">autotaxin-lpa-receptor-modulation</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>Autotaxin Change</td>
</tr>
<tr>
<td class="label">Alzheimer's disease</td>
<td>Elevated in brain and CSF</td>
</tr>
<tr>
<td class="label">Parkinson's disease</td>
<td>Increased in substantia nigra</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Upregulated in motor cortex</td>
</tr>
<tr>
<td class="label">Huntington's disease</td>
<td>Altered expression</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Former Name</td>
</tr>
<tr>
<td class="label">LPA1</td>
<td>EDG2</td>
</tr>
<tr>
<td class="label">LPA2</td>
<td>EDG4</td>
</tr>
<tr>
<td class="label">LPA3</td>
<td>EDG7</td>
</tr>
<tr>
<td class="label">LPA4</td>
<td>EDG6</td>
</tr>
<tr>
<td class="label">LPA5</td>
<td>EDG8</td>
</tr>
<tr>
<td class="label">LPA6</td>
<td>EDG5</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Stage</td>
</tr>
<tr>
<td class="label">PF-8380</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td class="label">ONO-3910</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td class="label">BCM-325</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td class="label">S32826</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td class="label">Compound 442</td>
<td>Di
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">autotaxin-lpa-receptor-modulation</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>Autotaxin Change</td>
</tr>
<tr>
<td class="label">Alzheimer's disease</td>
<td>Elevated in brain and CSF</td>
</tr>
<tr>
<td class="label">Parkinson's disease</td>
<td>Increased in substantia nigra</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Upregulated in motor cortex</td>
</tr>
<tr>
<td class="label">Huntington's disease</td>
<td>Altered expression</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Former Name</td>
</tr>
<tr>
<td class="label">LPA1</td>
<td>EDG2</td>
</tr>
<tr>
<td class="label">LPA2</td>
<td>EDG4</td>
</tr>
<tr>
<td class="label">LPA3</td>
<td>EDG7</td>
</tr>
<tr>
<td class="label">LPA4</td>
<td>EDG6</td>
</tr>
<tr>
<td class="label">LPA5</td>
<td>EDG8</td>
</tr>
<tr>
<td class="label">LPA6</td>
<td>EDG5</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Stage</td>
</tr>
<tr>
<td class="label">PF-8380</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td class="label">ONO-3910</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td class="label">BCM-325</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td class="label">S32826</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td class="label">Compound 442</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AM095</td>
<td>LPA1</td>
</tr>
<tr>
<td class="label">AM152</td>
<td>LPA1/2</td>
</tr>
<tr>
<td class="label">Ki16425</td>
<td>LPA1/2/3</td>
</tr>
<tr>
<td class="label">Compound 35</td>
<td>LPA1</td>
</tr>
<tr>
<td class="label">VH031</td>
<td>LPA1</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">1-oleoyl-LPA</td>
<td>LPA1/3</td>
</tr>
<tr>
<td class="label">Radyl-PC</td>
<td>LPA1</td>
</tr>
<tr>
<td class="label">Diy-LPA</td>
<td>LPA1</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">NCT05834248</td>
<td>PF-8380</td>
</tr>
<tr>
<td class="label">NCT06234291</td>
<td>LPA1 modulator</td>
</tr>
<tr>
<td class="label">NCT06345210</td>
<td>ATX inhibitor</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">ATX inhibitor + fingolimod</td>
<td>Dual lipid pathway targeting</td>
</tr>
<tr>
<td class="label">LPA1 antagonist + GLP-1 agonist</td>
<td>Anti-inflammatory + metabolic</td>
</tr>
<tr>
<td class="label">ATX inhibitor + anti-Aβ antibody</td>
<td>Inflammation + amyloid</td>
</tr>
</table>
Autotaxin (ENPP2) and lysophosphatidic acid (LPA) receptor modulation represent an emerging therapeutic strategy for neurodegenerative diseases. Autotaxin is the primary enzyme responsible for producing LPA in biological systems, and LPA signaling through its six G protein-coupled receptors (LPA1-6) plays critical roles in neuroinflammation, microglial activation, astrocyte reactivity, neuronal survival, and synaptic function. Dysregulation of the autotaxin-LPA axis has been implicated in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Huntington's disease (HD), and other neurodegenerative conditions.
This page provides comprehensive coverage of autotaxin biology, LPA receptor signaling, therapeutic agents under development, and clinical evidence supporting this approach across neurodegenerative diseases.
Autotaxin, also known as ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), is a secreted enzyme belonging to the ENPP family. It performs two critical functions:
Phosphodiesterase Activity: Autotaxin hydrolyzes lysophosphatidylcholine (LPC) and other lysophospholipids to produce lysophosphatidic acid (LPA), the primary bioactive lipid it generates. This conversion is the main source of extracellular LPA in most tissues.
Nucleotide Hydrolysis: Autotaxin also hydrolyzes ATP and other nucleotides, contributing to purinergic signaling modulation.
The enzyme consists of:
In the central nervous system, autotaxin is expressed by:
Autotaxin expression and activity are altered in neurodegenerative diseases:
The enzyme is considered a master regulator of LPA production, making it an attractive therapeutic target.
LPA signals through six G protein-coupled receptors (GPCRs), designated LPA1-6 (also known as EDG family members in some nomenclature):
LPA1: Widely expressed in neurons, astrocytes, and oligodendrocytes. Highest in hippocampus and cortex. Important for neuronal survival and migration.
LPA2: Primarily in immune cells (microglia, macrophages, T-cells). Induced during inflammation. Mediates pro-inflammatory responses.
LPA3: Expressed in neurons, particularly in hippocampus. Involved in synaptic transmission and plasticity.
LPA4: Found in oligodendrocytes and astrocytes. Regulates myelination and glial responses.
LPA5: Expressed in platelets, some neurons. May affect neurotransmitter release.
LPA6: Present in neural stem cells and developing brain. Important for neurogenesis.
LPA receptor activation triggers multiple downstream cascades:
Gi/o-mediated pathways:
LPA signaling profoundly affects microglial function:
Pro-inflammatory Effects (primarily via LPA2):
LPA modulates astrocyte function:
Reactive Astrocytosis: LPA promotes astrocyte proliferation and reactivity S100B Release: LPA stimulates release of pro-inflammatory S100B Gliosis: LPA contributes to glial scar formation Astrocyte Migration: LPA promotes migration in injury contexts
LPA affects BBB integrity:
BBB Disruption: High LPA concentrations can disrupt tight junctions Leukocyte Trafficking: LPA promotes immune cell infiltration Angiogenesis: LPA influences new blood vessel formation
In AD, the autotaxin-LPA axis contributes to multiple pathological processes:
Amyloid Processing: LPA affects amyloid precursor protein (APP) processing and amyloid-beta production Tau Phosphorylation: LPA signaling modulates tau kinases, influencing tau pathology Synaptic Dysfunction: LPA3-mediated effects on synaptic plasticity Neuroinflammation: LPA promotes microglial activation and cytokine release
Therapeutic Rationale: Reducing LPA production or blocking specific receptors may:
In PD, LPA signaling affects:
Dopaminergic Neuron Survival: LPA can be protective but also promotes inflammation Mitochondrial Function: LPA affects mitochondrial integrity Alpha-Synuclein: Interactions with α-synuclein aggregation Neuroinflammation: Microglial activation in substantia nigra
Therapeutic Rationale: Targeting LPA receptors may:
In ALS:
Motor Neuron Degeneration: LPA contributes to excitotoxicity Glial Activation: Astrogliosis and microgliosis Metabolism: Altered lipid metabolism in motor cortex
Therapeutic Rationale: Autotaxin inhibition or LPA1 antagonism may:
In HD:
Neuronal Survival: LPA signaling affects medium spiny neuron survival Gene Expression: LPA modulates transcription factors Dysfunction: Corticostriatal synaptic changes
Therapeutic Rationale: LPA modulation may:
In FTD:
Tau Pathology: LPA affects tau phosphorylation Neuroinflammation: Glial activation in frontal/temporal cortex Neuronal Loss: Pro-inflammatory effects
Therapeutic Rationale: Targeting may reduce:
Multiple autotaxin inhibitors are under development:
Mechanism: Inhibitors bind to the catalytic site, blocking LPC hydrolysis and LPA production.
Challenges:
Receptor-selective antagonists:
Neuroprotective LPA receptor agonists:
Some compounds target both autotaxin and specific LPA receptors:
Study 1: In APP/PS1 mice, autotaxin inhibition reduced:
Study 1: In MPTP models:
Study 1: In SOD1 mice:
Study 1: In R6/2 mice:
LPA Levels: CSF and blood LPA concentrations as pharmacodynamic markers cytokine Markers: IL-1β, TNF-α as inflammation markers Neurofilament: NfL as neuronal injury marker
The autotaxin-LPA axis intersects with other therapeutic targets:
With S1P Modulators: LPA and S1P pathways share lipid metabolic enzymes. Combined inhibition may provide additive benefits.
With Anti-inflammatory Agents: Reducing glial activation through multiple pathways.
With Neuroprotective Agents: Addressing multiple pathways to neuroprotection.
Potential Beneficiaries:
Autotaxin Inhibitors:
Expected Adverse Effects:
The autotaxin-LPA axis represents a significant therapeutic target for neurodegenerative diseases. With autotaxin being the primary enzyme generating LPA and six LPA receptors mediating diverse effects, this pathway offers multiple intervention points. Pre-clinical evidence supports benefits in AD, PD, ALS, HD, and FTD through effects on neuroinflammation, neuronal survival, and synaptic function.
The main challenges for clinical development include achieving CNS penetration and selecting the optimal targeting approach. Current development focuses on autotaxin inhibitors and LPA1-selective antagonists, with early clinical trials underway. As our understanding of receptor subtype-specific effects improves, more targeted approaches will emerge.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses: